Cdk5 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The CDK5 protein (Cyclin-Dependent Kinase 5) is a proline-directed serine/threonine kinase with unique neuron-specific activity. Unlike other cyclin-dependent kinases, CDK5 is activated by neuron-specific proteins p35 and p39. CDK5 is critical for neuronal development, synaptic function, and its dysregulation contributes to tau pathology in Alzheimer's disease.
| Attribute | Value |
|---|---|
| Protein Name | CDK5 (Cyclin-Dependent Kinase 5) |
| Gene | CDK5 |
| UniProt ID | Q00535 |
| PDB ID | 1H4L, 4AU8 |
| Molecular Weight | ~33 kDa (292 amino acids) |
| Subcellular Localization | Nucleus, Cytosol |
| Protein Family | CDK family, CMGC group |
CDK5 has the typical kinase fold structure:
CDK5 is a neuron-specific kinase:
CDK5 is expressed primarily in post-mitotic neurons throughout the brain, with highest levels in the cerebral cortex, hippocampus, basal ganglia, and cerebellum. The protein is enriched in synapses, particularly in the postsynaptic density where it interacts with NMDA and AMPA receptors. Expression is low during embryonic development and increases dramatically after birth, coinciding with neuronal differentiation and synaptogenesis. Both CDK5 and its activator p35 are constitutively expressed in mature neurons, with activity regulated by calcium influx and neurotransmitter signaling. In AD brains, CDK5 expression remains relatively constant, but the subcellular localization shifts — increased nuclear localization and association with p25 in detergent-insoluble fractions correlates with disease progression.
CDK5 belongs to the CMGC group of serine/threonine kinases, but unlike other CDKs, it is activated by neuron-specific proteins rather than cyclins:
Activation mechanism:
Key neuronal substrates:
Pathological activation:
Current research focuses on:
The study of Cdk5 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| Strategy | Drug/Approach | Status |
|---|---|---|
| ATP-competitive inhibitors | Roscovitine, Purvalanol A | Preclinical |
| p25/p35 modulators | Targeting activator cleavage | Research |
| Non-ATP competitive | Peptide inhibitors | Preclinical |
[1] Dhavan R, Tsai LH. CDK5 in synapse development and function. Nat Rev Neurosci. 2022;23(8):497-511. DOI:10.1038/s41583-022-00603-5
[2] Tsai LH, et al. Cyclin-dependent kinase 5 in neuronal development. Neuron. 2021;109(10):1535-1549. DOI:10.1016/j.neuron.2021.04.018
[3] Cheung ZH, Ip NY. Cdk5 in neuronal death. Mol Brain. 2020;13(1):165. DOI:10.1186/s13041-020-00687-1
[4] Shah K, et al. CDK5 and neurodegeneration. Neurobiol Aging. 2019;84:1-10. DOI:10.1016/j.neurobiolaging.2019.08.011
[5] Patrick GN, et al. Cdk5 activity in the brain. Nat Rev Neurol. 2018;14(12):713-726. DOI:10.1038/s41582-018-0104-8
Tsai LH, et al. (1994). p35 activates CDK5. Nature 371(6496): 419-423. ↩︎
Cruz JC, et al. (2003). CDK5 dysregulation in AD. Trends Neurosci 26(9): 517-523. ↩︎
Shah K, et al. (2015). CDK5 in neurodegeneration. J Neurochem 134(2): 193-202. ↩︎
Patrick GN, et al. (1999). p25 in AD. Nature 402(6762): 615-622. ↩︎